Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that they have been awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the annual Drug Development Boot Camp November 15-16, 2017 at the Harvard Club in Boston, MA. The Drug Development Boot Camp is hosted by Speid & Associates, Inc., in coordination with Harvard’s Office of Technology Development, and is a two-day intensive program for executive-level individuals that involves hands-on learning about the drug development process.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic systems modeling, simulation, and analysis to de-risk drug research and development, today announces their upcoming participation at PEGS: The Essential Protein Engineering Summit being held April 30 - May 4, 2018 in Boston, MA. Applied BioMath is sponsoring, exhibiting, presenting a poster, and presenting two talks at the conference.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic mathematical modeling, simulation, and analysis to de-risk therapeutic research and development, today announced a collaboration with Checkpoint Therapeutics, Inc., for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling in advanced metastatic solid tumors.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform semi-mechanistic PK/PD modeling to analyze Xencor's XmAb® IL15/IL15Rα-Fc program for the treatment of solid tumors. The collaboration will focus on developing a mathematical model relating XmAb®24306 modulated potency and extended half-life to observed pharmacokinetics and in vivo T-cell stimulation.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced a collaboration with Pandion Therapeutics for semi-mechanistic pharmacokinetic and target occupancy (PK/TO) modeling in Autoimmune Disease.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to drug research and development, today announced their newest Science Advisory Board member, Dhaval K. Shah, PhD.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Compass Therapeutics for the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species and will help answer strategic questions such as the target coverage required for efficacy and dose regimen selection for the clinical study.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the annual Drug Development Boot Camp November 15-16, 2017 at the Harvard Club in Boston, MA. The Drug Development Boot Camp is hosted by Speid & Associates, Inc., in coordination with Harvard's Office of Technology Development, and is a two-day intensive program for executive-level individuals that involves hands-on learning about the drug development process.
Applied BioMath® (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at PepTalk: The Protein Science Week being held January 8-12, 2018 in San Diego, California.
Applied BioMath® (www.appliedbiomath.com), the industry leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune's ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune's lead drug candidate, SYNT001.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that Dr. Douglas A. Lauffenburger has joined the speaker lineup for QSP Day 2018. The conference occurs Thursday, April 12, 2018 from 9:00 a.m. - 5:00 p.m. at the Samberg Conference Center, MIT Chang Building in Cambridge, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the Antibody Engineering and Therapeutics Conference December 11-15, 2017 in San Diego, CA. John Burke, PhD, will present Model Aided Drug Invention (MADI) case studies on Thursday, December 14, 2017 at 12:00 p.m. In addition to speaking at the event, Applied BioMath is also participating as a scientific briefing sponsor.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in FierceBiotech’s second Drug Development Forum occurring September 25-27, 2017 in Boston, MA. Applied BioMath will be a sponsor as well as presenter at the event.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the upcoming American Conference on Pharmacometrics (ACoP) occurring October 15-18, 2017 in Fort Lauderdale, FL. Applied BioMath will be a conference sponsor, exhibitor, and poster presenter. Applied BioMath’s posters will highlight several examples of model-aided drug invention (MADI) by presenting case studies in immuno-oncology, osteoarthritis, and antibody-drug conjugates. More specifically, they will show:
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the World Bispecific Summit occurring September 26-28, 2017 in Boston, MA. In addition to sponsoring and exhibiting at the 8th annual summit, Dr.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in an upcoming quantitative systems pharmacology (QSP) event hosted by the Pharmaceutical and BioScience Society on September 29, 2017 in Boston, MA. Applied BioMath is the sole major sponsor of the day-long event as well as a presenter of two case studies in immuno-oncology and osteoarthritis.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced an extension of their collaboration with Zymeworks Inc. for quantitative systems pharmacology (QSP) support for antibody drug conjugate therapeutics intended for the treatment of cancer.
Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that Louis J. Latino, Jr. is joining its team as Senior Vice President of Business Development. In this role, Lou will lead the Applied BioMath business development team and continue to develop the company's growth strategy in the biotechnology and pharmaceutical industry.
Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, announced their collaboration with Tusk Therapeutics for quantitative systems pharmacology (QSP) modeling and analysis to enable preclinical candidate selection in immuno-oncology. Applied BioMath leveraged its proprietary mechanistic modeling platform to develop a QSP model of one of Tusk Therapeutics' targets and antibody candidates, then analyzed this model to identify optimal drug properties to aid preclinical candidate selection.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, will present at Drug Development Boot Camp on November 16-17, 2016 at The Harvard Club in Boston, MA. This intensive two-day program, organized by Harvard University and Speid & Associates, allows executive level biotech and pharmaceutical scientists to share successes and challenges of the drug development process.